• slidebg1

    Collaborate

    CRISPR is an early-stage company
    created to translate breakthrough
    gene-editing technology into transformative
    medicines for serious human diseases.
    Abingworth is helping CRISPR to select
    its first therapeutic indications
    and build its team.

  • slidebg1

    Innovate

    Nasdaq-listed Paratek is developing novel
    antibiotics to tackle community-acquired
    infections. Abingworth helped recruit the
    team and co-led the investment.

  • slidebg1

    Create

    Pixium is restoring vision and autonomy
    to the blind. Abingworth has supported
    the French company from its inception to its
    IPO on Euronext.

  • slidebg1

    Collaborate

    Abingworth is working with US-based
    Gynesonics to develop a minimally
    invasive treatment for symptomatic
    uterine fibroids.

  • slidebg1

    Innovate

    Personalis provides researchers and
    clinicians with advanced genome sequencing
    and interpretation services for inherited
    genetic diseases and cancer. Abingworth
    led the series A financing.

  • slidebg1

    Create

    Abingworth is supporting Swedish-based
    Wilson to develop a de-coppering agent for
    the orphan indication Wilson’s disease.

Latest News
16 Sep 2016
GammaDelta Therapeutics Raises Seed Funding from Abingworth   Read More
25 Jul 2016
Pixium Vision announces CE market approval of IRIS®II, its first bionic vision system  Read More
24 Jun 2016
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing   Read More
 

Home

About Us

  1. About Us
  2. Our Team
  3. Transatlantic Reach
  4. Funds

Strategy

  1. Our Strategy
  2. Venture Capital
  3. Clinical Co‑development
  4. VIPEs
  5. Public Markets

Portfolio

  1. Portfolio Companies
  2. Case Studies

Media Centre

  1. Recent News
  2. Archived News

Contact

  1. Contact Us
  2. Send Us Your Proposal
Collaborate
CRISPR is an early-stage company created to translate breakthrough gene-editing technology into transformative medicines for serious human diseases. Abingworth is helping CRISPR to select its first therapeutic indications and build its team.
Innovate
Nasdaq-listed Paratek is developing novel antibiotics to tackle community-acquired infections. Abingworth helped recruit the team and led the investment.
Create
Pixium is restoring vision and autonomy to the blind. Abingworth has supported the French company from its inception to its IPO on Euronext.
Collaborate
Abingworth is working with US-based Gynesonics to develop a minimally invasive treatment for symptomatic uterine fibroids.
Innovate
Personalis provides researchers and clinicians with advanced genome sequencing and interpretation services for inherited genetic diseases and cancer. Abingworth led the series A financing.
Create
Abingworth is supporting Swedish-based Wilson to develop a de-coppering agent for the orphan indication, Wilson’s disease.
 
Latest News
16 Sep 2016
GammaDelta Therapeutics Raises Seed Funding from Abingworth   Read More
25 Jul 2016
Pixium Vision announces CE market approval of IRIS®II, its first bionic vision system  Read More
24 Jun 2016
CRISPR Therapeutics Raises Additional $38M as Part of Series B Financing   Read More
Copyright Abingworth 2016